PADMANEE SHARMA to Macrophages
This is a "connection" page, showing publications PADMANEE SHARMA has written about Macrophages.
Connection Strength
0.806
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.359
-
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun. 2024 Jul 10; 15(1):5291.
Score: 0.149
-
Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023 02; 23(2):106-120.
Score: 0.129
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
Score: 0.109
-
Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
Score: 0.033
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.028